市場調查報告書

高鉀血症治療的全球市場:成長,趨勢,及預測

Hyperkalemia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921259
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
高鉀血症治療的全球市場:成長,趨勢,及預測 Hyperkalemia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 110 Pages
簡介

高鉀血症,是由於各種藥物的使用,腎功能障礙,以及電解質不均衡等其他原因可能發生的威脅生命的疾病。癌症和腸胃疾病的盛行率增加伴隨的高鉀血症的增加,對研究開發的關注高漲和策略性聯盟的增加,使高鉀血症治療市場成長。但,藥物的高成本是妨礙該市場成長的要素。

本報告提供全球量鉀血症市場的相關調查,市場機會和趨勢,成長及阻礙因素,各藥物、疾病類型、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 高鉀血症的盛行率增加
    • 研究開發的關注高漲和策略性聯盟的增加
  • 阻礙市場要素
    • 藥物的高成本
  • 波特的五力分析

第5章 市場區隔

  • 各藥物
    • Sodium zirconium cyclosilicate
    • Patriomer
    • Beta2促效劑
    • 利尿劑
    • 聚苯乙烯磺酸鹽酸鈉
    • 其他
  • 各疾病類型
    • 急性高鉀血症
    • 慢性高鉀血症
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • AstraZeneca Plc
    • Ardelyx
    • Perrigo
    • Vifor Pharma Management Ltd.
    • Sanofi SA

第7章 市場機會及今後趨勢

目錄
Product Code: 67105

Market Overview

Hyperkalemia, a life-threatening condition, can occur due to various medication use, kidney dysfunction, or alternative sources of electrolyte disparity. The cases of hyperkalemia have been rising with the increasing prevalence of cancer and gastrointestinal disease. Hyperkalemia has been reported in less than 5% of the general population worldwide. The incidence and prevalence of hyperkalemia have been estimated to be 2-3% in the general population and 1% to 10% among hospitalized patients. Also, people with chronic kidney disease, heart failure, diabetes mellitus, and those taking blood pressure medicines called renin-angiotensin-aldosterone system inhibitors (RAASi) have an estimated 2 to 3 times higher risk for hyperkalemia.

Scope of the Report

Hyperkalemia, defined as a serum potassium concentration greater than 5.0-5.3 mEq/L, which is found to be rare in a general population of healthy individuals. The report covers the market trends of the medication used for acute and chronic hyperkalemia.

Key Market Trends

Chronic hyperkalemia dominates the Global Hyperkalemia Treatment Market

Chronic hyperkalemia is usually related to impaired renal excretion. Chronic hyperkalemia is usually asymptomatic, hence the treatment goals include prevention of generalized symptoms, cardiac dysrhythmias, and death. Treatment of chronic hyperkalemia includes diuretics, bicarbonate salts, dietary restriction, potassium binders, and dialysis. Also, chronic hyperkalemia is one of the major complications of chronic kidney disease (CKD) that occurs frequently and requires careful management by the nephrologist. This segment is projected to lead the global market throughout the forecast period.

North America Dominates the Global Hyperkalemia Treatment Market

North America holds a leading position in the hyperkalemia treatment market owing to advanced medical technology and rising aging populations which are likely to contribute to increased prevalence of heart failure and chronic kidney disease and accordingly a larger pool of patients at risk for hyperkalemia. An estimated 3.7 million US adults had hyperkalemia in the year 2014, and this prevalence rate has been increasing since 2010. In patients with CKD and/or heart failure, the annual prevalence of hyperkalemia was 6.35% in 2014, and about half of all patients with hyperkalemia have either CKD and/or heart failure. Easy access to medication, raising awareness, and favorable reimbursement are the key factors driving the market in this region.

Competitive Landscape

The hyperkalemia market is consolidated, dominated by a few players. The hyperkalemia market underwent extensive changes with the introduction of Veltassa at the beginning of 2016 which represented the first new therapy for the treatment of hyperkalemia in over 50 years. Few key market players in the market are AstraZeneca Plc, Ardelyx, Vifor Pharma Management Ltd, Sanofi S.A., and Perrigo Company plc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Hyperkalemia
    • 4.2.2 Rising Focus on Research and Development and Increasing Number of Strategic Alliances
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Drugs
    • 5.1.1 Sodium zirconium cyclosilicate
    • 5.1.2 Patriomer
    • 5.1.3 Beta2 Agonist
    • 5.1.4 Diuretics
    • 5.1.5 Sodium Polystyrene Sulfonate
    • 5.1.6 Others
  • 5.2 Type of Disease
    • 5.2.1 Acute Hyperkalemia
    • 5.2.2 Chronic Hyperkalemia
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca Plc
    • 6.1.2 Ardelyx
    • 6.1.3 Perrigo
    • 6.1.4 Vifor Pharma Management Ltd.
    • 6.1.5 Sanofi S.A.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS